EGenesis

company

About

EGenesis focuses on leveraging genome editing technology to deliver safe and effective human transplantable cells, tissues, and organs.

  • 1 - 10

Details

Last Funding Type
Series B
Last Funding Money Raised
$100M
Industries
Biopharma,Biotechnology,Genetics,Life Science,Medical
Founded date
Jan 1, 2014
Number Of Employee
1 - 10
Operating Status
Active

EGenesis operates as a biotechnology company. The Company focuses on leveraging genome editing technology to deliver safe and effective human transplantable cells, tissues, and organs. eGenesis serves patients worldwide.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
$263M
EGenesis has raised a total of $263M in funding over 2 rounds. Their latest funding was raised on Mar 2, 2021 from a Series C round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Mar 2, 2021 Series C $125M 1 Detail
Nov 7, 2019 Series B $100M 2 Detail
Mar 16, 2017 Series A $38M 2 ARCH Venture Partners Detail

Investors

Number of Lead Investors
Number of Investors
1
3
EGenesis is funded by 3 investors. ARCH Venture Partners and Bayer are the most recent investors.
Investor Name Lead Investor Funding Round
ARCH Venture Partners Series C
Bayer Series B
Fan Ventures Series A